文献速递肥胖与代谢综合征

临床肥胖的定义和诊断标准

Definition and diagnostic criteria of clinical obesity.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-01-14

该委员会由58名多学科专家(含肥胖亲历者)通过共识制定流程,将肥胖定义为脂肪过多症,并区分临床肥胖与临床前肥胖。推荐BMI仅用于人群筛查,需结合体脂测量或人体测量指标确认脂肪过多;临床肥胖诊断需满足器官功能受损或年龄调整的日常活动受限标准。所有推荐共识度达90–100%,获76个组织认可。

要点

  • BMI仅作为人群健康风险的替代指标或筛查工具,不作为个体健康度量。
  • 临床肥胖诊断需满足器官/组织功能受损或年龄调整的日常活动受限之一或两者。
  • 临床前肥胖应接受健康咨询、监测,并酌情干预以降低进展风险。

核心结论

  • 临床肥胖被定义为由脂肪过多导致组织、器官或个体功能改变的慢性系统性疾病的疾病状态。
  • 临床前肥胖被定义为脂肪过多但其他组织器官功能保留、临床肥胖及非传染性疾病风险增高的状态。

研究设计与样本

  • 该委员会由58名代表多学科和多个国家的专家(包括肥胖亲历者)讨论现有证据并参与共识制定流程。

主要发现

  • 临床肥胖可导致严重终末器官损伤,引起改变生活且可能危及生命的并发症(如心脏病发作、卒中和肾衰竭)。
  • 临床前肥胖与临床肥胖的风险在脂肪量增加时呈连续上升,但为临床和政策目的仍区分二者(健康 vs 疾病)。
  • 所有推荐在委员中达成最高共识(共识度90–100%),并获76个组织(包括科学学会和患者倡导团体)认可。

关键数值与推荐

  • 推荐BMI仅用于人群水平健康风险替代指标、流行病学研究或筛查,而非个体健康度量。
  • 脂肪过多应通过直接体脂测量(若有条件)或至少一项人体测量指标(如腰围、腰臀比或腰高比)结合BMI确认,使用经过验证且适合年龄、性别和种族的方法和切点。
  • BMI>40 kg/m2者,可务实地假定脂肪过多,无需进一步确认。
  • 临床肥胖诊断需满足以下主要标准之一或两者:有证据表明肥胖导致器官或组织功能下降(即体征、症状或诊断测试显示一个或多个组织或器官系统功能异常);或反映肥胖对活动能力、其他基本日常生活活动(如洗澡、穿衣、如厕、控便和进食)或两者具体影响的实质性年龄调整日常活动受限。

临床怎么用

  • 临床肥胖者应接受及时、循证的治疗,旨在改善(或可能时缓解)肥胖的临床表现并预防进展为终末器官损伤。
  • 临床前肥胖者应接受循证健康咨询、随时间监测健康状况,并酌情进行适当干预以降低发展为临床肥胖和其他肥胖相关疾病的风险,干预应与个体健康风险水平相适应。
  • 政策制定者和卫生当局应确保临床肥胖个体充分且公平地获得可用的循证治疗,如同对待慢性和可能危及生命的疾病患者。
  • 减少肥胖发病率和患病率的公共卫生策略必须基于当前科学证据,而非未经验证的假设将肥胖发展归咎于个人责任。
  • 体重相关的偏见和污名是有效预防和治疗肥胖的主要障碍;卫生专业人员和政策制定者应接受适当培训以解决这一重要问题。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current BMI-based measures of obesity can both underestimate and overestimate adiposity and provide inadequate information about health at the individual level, which undermines medically-sound approaches to health care and policy. This Commission sought to define clinical obesity as a condition of illness that, akin to the notion of chronic disease in other medical specialties, directly results from the effect of excess adiposity on the function of organs and tissues. The specific aim of the Commission was to establish objective criteria for disease diagnosis, aiding clinical decision making and prioritisation of therapeutic interventions and public health strategies. To this end, a group of 58 experts—representing multiple medical specialties and countries—discussed available evidence and participated in a consensus development process. Among these commissioners were people with lived experience of obesity to ensure consideration of patients’ perspectives. The Commission defines obesity as a condition characterised by excess adiposity, with or without abnormal distribution or function of adipose tissue, and with causes that are multifactorial and still incompletely understood. We define clinical obesity as a chronic, systemic illness characterised by alterations in the function of tissues, organs, the entire individual, or a combination thereof, due to excess adiposity. Clinical obesity can lead to severe end-organ damage, causing life-altering and potentially life-threatening complications (eg, heart attack, stroke, and renal failure). We define preclinical obesity as a state of excess adiposity with preserved function of other tissues and organs and a varying, but generally increased, risk of developing clinical obesity and several other non-communicable diseases (eg, type 2 diabetes, cardiovascular disease, certain types of cancer, and mental disorders). Although the risk of mortality and obesity-associated diseases can rise as a continuum across increasing levels of fat mass, we differentiate between preclinical and clinical obesity (ie, health vs illness) for clinical and policy-related purposes. We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health. Excess adiposity should be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (eg, waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, gender, and ethnicity. In people with very high BMI (ie, >40 kg/m2), however, excess adiposity can pragmatically be assumed, and no further confirmation is required. We also recommend that people with confirmed obesity status (ie, excess adiposity with or without abnormal organ or tissue function) should be assessed for clinical obesity. The diagnosis of clinical obesity requires one or both of the following main criteria: evidence of reduced organ or tissue function due to obesity (ie, signs, symptoms, or diagnostic tests showing abnormalities in the function of one or more tissue or organ system); or substantial, age-adjusted limitations of daily activities reflecting the specific effect of obesity on mobility, other basic activities of daily living (eg, bathing, dressing, toileting, continence, and eating), or both. People with clinical obesity should receive timely, evidence-based treatment, with the aim to induce improvement (or remission, when possible) of clinical manifestations of obesity and prevent progression to end-organ damage. People with preclinical obesity should undergo evidence-based health counselling, monitoring of their health status over time, and, when applicable, appropriate intervention to reduce risk of developing clinical obesity and other obesity-related diseases, as appropriate for the level of individual health risk. Policy makers and health authorities should ensure adequate and equitable access to available evidence-based treatments for individuals with clinical obesity, as appropriate for people with a chronic and potentially life-threatening illness. Public health strategies to reduce the incidence and prevalence of obesity at population levels must be based on current scientific evidence, rather than unproven assumptions that blame individual responsibility for the development of obesity. Weight-based bias and stigma are major obstacles in efforts to effectively prevent and treat obesity; health-care professionals and policy makers should receive proper training to address this important issue of obesity. All recommendations presented in this Commission have been agreed with the highest level of consensus among the commissioners (grade of agreement 90–100%) and have been endorsed by 76 organisations worldwide, including scientific societies and patient advocacy groups.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025. PMID: 39824205. doi:10.1016/S2213-8587(24)00316-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。